featured
Panitumumab vs Cetuximab in Metastatic CRC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Panitumumab Versus Cetuximab in Patients With Chemotherapy-Refractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer (ASPECCT): A Randomised, Multicentre, Open-Label, Non-Inferiority Phase 3 Study
Lancet Oncol 2014 May 01;15(6)569-79, TJ Price, M Peeters, TW Kim, J Li, S Cascinu, P Ruff, AS Suresh, A Thomas, S Tjulandin, K Zhang, S Murugappan, R SidhuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.